Neurologic Disorders

Rituximab associated with lower drug discontinuation and disease relapse rates in multiple sclerosis

January 10, 2018

Rituximab was associated with lower discontinuation rates as compared to other disease-modifying treatments in newly diagnosed patients with relapsing-remitting multiple sclerosis.

Disappointing Results From Latest Trial of Prospective Alzheimer Tx

January 10, 2018

The researchers found that the mean change in the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale was 0.37, 0.61, and 0.41 for the 60- and 30-mg idalopirdine groups and the placebo group, respectively.

Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

By January 09, 2018

Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

New Guidelines Published on Opioid Use in Refractory RLS Treatment

By January 09, 2018

Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.

First-Line Disease-Modifying Txs Compared for Relapsing-Remitting MS

January 09, 2018

Of the 494 patients, 43.5% received an injectable DMT, 17.4% dimethyl fumarate, 3.4% fingolimod, 10.1% natalizumab, 24.3% rituximab, and 1.2% other DMT.

Caffeine Metabolism and Parkinson's Disease: What's the Link?

January 04, 2018

Significant decreases in serum levels of caffeine and nine of its metabolites seen in patients with early PD

Impact of Maternal Folate Status on Child's Autistic Traits After AED Exposure

By December 28, 2017

Children exposed to antiepileptic drugs (AEDs) in utero may have a reduced risk of autistic traits with periconceptional folic acid supplementation and folate status

More Than a Third of Patients Do Not Respond to Antiepileptics

December 28, 2017

Overall, 89.9% of patients who achieve seizure control do so with first, second AED regimen

Epidiolex Under Review for Two Childhood-Onset Epilepsy Conditions

By December 28, 2017

Epidiolex is a pharmaceutical formulation of purified cannabidiol

Consumption of Green Leafy Vegetables May Slow Cognitive Decline

December 21, 2017

Consumption of median 1.3 servings/day over 4.7 years tied to slower cognitive decline

Treatment for Angelman Syndrome Gets Fast Track Status

By December 19, 2017

Angelman syndrome affects approximately 1 in 12,000 to 20,000 in the U.S. and symptoms include delayed development, intellectual disability, and seizures.

Interventions Reviewed for Late-Life Dementia Prevention

December 19, 2017

Researchers from the University of Minnesota in Minneapolis reviewed data from 32 trials to examine the effectiveness of physical activity interventions in slowing cognitive decline and delaying the onset of cognitive impairment and dementia.

Fingolimod Gets Breakthrough Therapy Designation for Pediatric MS

By December 18, 2017

The FDA has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple sclerosis (MS).

Vercise Deep Brain Stimulation System Approved for Parkinson's Disease

By December 12, 2017

The FDA's approval was based on results from the 'Intrepid' study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for Parkinson's Disease in the U.S.

Enzalutamide Seizure Risk Factor Assessed in mCRPC

December 08, 2017

Within 4 months of enzalutamide initiation, four patients (1.1%) had at least one confirmed seizure; three additional patients (0.8%) experienced a seizure within four months following the 4-month study period.

Model Projects Alzheimer's Disease to Double in U.S. by 2060

December 08, 2017

A differential impact is anticipated for primary and secondary preventions on future disease burden.

Do Certain Medications Increase the Risk of MS Development?

By December 07, 2017

No drug treatments were conclusively associated with an increased risk of MS.

Diet Quality May Affect MS Disability Severity

December 07, 2017

The researchers found that having dietary quality scores in the highest versus the lowest quintile correlated with lower levels of disability.

New Study Sheds Light on Safety of Gadolinium-Based Contrast Agents

By November 29, 2017

After adjusting for gender, age, education level, baseline neurocognitive performance, and others, the authors reported gadolinium exposure was not a significant predictor of cognitive decline, dementia, diminished neuropsychological performance or diminished motor performance

Anticholinergic Scoring Systems Appraised in Clinical Settings

November 28, 2017

The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years.

Percutaneous Transluminal Angioplasty Examined in MS Patients

November 27, 2017

There was no difference in the composite functional measure (walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) between the PTA and sham groups (41.7 vs. 48.7%; odds ratio, 0.75; 95% confidence interval, 0.34 to 1.68; P=0.49).

Cervical Dystonia Drug Candidate Gets Orphan Drug Designation

By November 21, 2017

Treatments for cervical dystonia include oral medications, botulinum toxin injections, surgery, and complementary therapies.

Agranulocytosis Cases Prompt More Monitoring for Investigational Parkinson's Drug

By November 16, 2017

Dependent on further input from the Data Safety Monitoring Board (DSMB) and the Food and Drug Administration (FDA), the Company stated that they intend on moving forward with the study and expect to report results in the first quarter of 2018.

Early cART, Viral Suppression May Minimize Brain Injury in HIV Patients

November 15, 2017

No significant neuropsychological decline during two-year period with combination antiretroviral therapy

Long-Term Effects of Valbenazine Examined in Adults With Tardive Dyskinesia

By November 14, 2017

Maintenance of treatment effect was demonstrated with both doses.

New Immunoassays Show Improvement in Measuring Aβ42 in CSF

November 09, 2017

The researchers found that the mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST, Aβ42-FL, Aβ42-EI, and Aβ42-MSD assays versus the classic Aβ42-INNOTEST assay.

Previous West Nile Infection Linked to Neurologic Abnormalities

November 09, 2017

Data were included for 262 patients with a history of WNV enrolled in a longitudinal cohort from 2002 to 2012; 117 patients underwent neurologic and neurocognitive evaluations.

Sodium Oxybate Evaluated for Sleep-Wake Disturbances in PD Patients

November 08, 2017

Improvements in subjective sleep quality, objectively measured slow-wave sleep duration

Vimpat Approved to Treat Partial-Onset Seizures in Children

By November 06, 2017

Clinicians can prescribe Vimpat to their pediatric patients either as an oral solution or a tablet.

Nusinersen Beneficial in Infantile-Onset Spinal Muscular Atrophy

November 02, 2017

In additiona, a gene replacement therapy was found to be beneficial in spinal muscular atrophy type 1 (SMA1).